Skip to main content

Year: 2023

GeoVax Reports Third Quarter 2023 Financial Results and Provides Business Update

Significant Progress towards data milestones in Phase 2 Program of GEO-CM04S1, Next-generation COVID-19 vaccine Gedeptin® clinical data from Phase 1/2 study presented at AACR-AHNS Head and Neck Cancer Conference showing safe administration and tumor reduction Multi-Product License Secured for ProBioGen’s AGE1.CR.pIX® suspension cell line to enhance manufacturing capabilities of MVA-based vaccine portfolio Company to host conference call and webcast today at 4:30 p.m. ET ATLANTA, GA, Nov. 08, 2023 (GLOBE NEWSWIRE) — via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced financial results for the third quarter ended September 30, 2023 and provided a business update. “We are thrilled to see material advancements...

Continue reading

Dyadic Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress

Received an upfront payment of $0.6 million in October for product development and licensing of our Dapibus™ platform for animal-free dairy enzyme productsDYAI-100 Phase 1 clinical trial top-line results expected in December 2023New research collaboration with Vaccine and Immunotherapy Center at Massachusetts General Hospital as part of US $5.88 million awards from the Department of Defense (“DoD”)New development and commercialization agreement with bYoRNA to develop cost-effective messenger RNA (mRNA)Ongoing preclinical animal studies showing positive results with high neutralizing antibody levels for seasonal and pandemic flu and other infectious diseasesExpanded leadership team to support increased business development activities Entered multiple new research collaborations and product development agreementsAdvanced...

Continue reading

Akoya Reports Record Revenue in the Third Quarter of 2023 and Reiterates Full Year 2023 Revenue Guidance

Q3 2023 revenue $25.2 million, 34% y/y growth Reiterating FY 2023 revenue guidance range of $95-98 million MARLBOROUGH, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) — Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced its financial results for the third quarter ending September 30, 2023. “Akoya delivered strong financial performance in the third quarter with another record revenue quarter while maintaining operating expenses at a steady or reduced level, solidifying the path towards achieving positive cash flow,” explained Brian McKelligon, Chief Executive Officer of Akoya Biosciences. “We are executing on our plan to improve workflow throughput, with the ongoing 2.0 instrument field upgrades across the industry’s largest installed base and by expanding our menu of ready-to-use...

Continue reading

Interpace Biosciences Announces Record Third Quarter 2023 Financial and Business Results

  ● Q3 Revenue of $9.1 million; an 11% increase year-over-year  ● Q3 Test volume up 11% year-over-year  ● Q3 Reimbursement improvement up 11% year-over-year, driven by additional commercial contracts and collection initiatives     PARSIPPANY, NJ, Nov. 08, 2023 (GLOBE NEWSWIRE) — Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the third quarter ended September 30, 2023 and provided a business and financial update. Third quarter Net Revenue was $9.1 million, a $0.9 million increase over third quarter 2022. Loss from continuing operations in the third quarter of 2023 was $0.5 million, an improvement of $0.7 million from the prior-year quarter’s loss of $1.3 million. On an adjusted basis, EDITDA was $0.4 million in Q3 and $2.9 million for YTD 2023. Net of...

Continue reading

Accolade To Present at Stephens Annual Investment Conference

SEATTLE, Nov. 08, 2023 (GLOBE NEWSWIRE) — Accolade, Inc. (NASDAQ: ACCD), a healthcare provider that serves millions of members, today announced that it will be presenting at the Stephen Annual Investment Conference in Nashville on Wednesday, November 15, 2023 at 11:00am CT. A webcast of the company’s fireside chat will be available at ir.accolade.com and a replay will be available for 90 days. About Accolade, Inc. Accolade (Nasdaq: ACCD) is a Personalized Healthcare company that provides millions of people and their families with exceptional healthcare experiences so they can live their healthiest lives. Accolade’s employer, health plan, and consumer solutions combine virtual primary care and mental health, expert medical opinion, and best-in-class care navigation. These offerings are built on a platform that is engineered to care...

Continue reading

20231108 – Worldline – Statement post S&P rating decision

Rating change to BBB- by S&P Global Ratings Worldline maintains Investment Grade Paris La Défense, 08 November 2023 – S&P Global Ratings (S&P) lowered the issuer credit rating of Worldline (the “Company”) from BBB to BBB-, with a stable outlook. The company takes note of the decision, which is driven by a longer than expected deleveraging process. S&P’s perception of Worldline as a solid business remains intact, while the group’s liquidity level is classified as “exceptional”. This rating change should have marginal impacts on the company’s financing.Worldline benefits from ample liquidity resources (€1.2bn cash position and undrawn €1bn RCF as at Jun-23) and faces no short-term maturities as 2024 bonds have already been pro-actively addressed via a new bond issuance in September 2023 and bonds buyback. Worldline...

Continue reading

Ponce Financial Group, Inc. Announces Participation in a Virtual Bank Conference

NEW YORK, Nov. 08, 2023 (GLOBE NEWSWIRE) — Ponce Financial Group, Inc., (the “Company”) (NASDAQ: PDLB), the holding company for Ponce Bank (the “Bank”), announced that it will be presenting at a virtual bank conference hosted by Sycamore Analytics and Pendragon Capital Management on November 9, 2023 from 10:25 to 10:55 AM. In addition, Sundie Seefried, CEO of SHF Holdings, Inc. and Mike Godby, Managing Director of Janney Montgomery Scott will be presenting. To register for the event visit www.VirtualBankConference.com. About Ponce Financial Group, Inc. Ponce Financial Group, Inc., is the holding company for Ponce Bank. Ponce Bank is a Minority Depository Institution, a Community Development Financial Institution, and a certified Small Business Administration lender. Ponce Bank’s business primarily consists of taking deposits from...

Continue reading

Commissioning of the Montclar solar farm

Commissioning of the Montclar solar farm Voltalia (Euronext Paris, ISIN code: FR0011995588), an international player in renewable energies, announces the start of production of the Montclar solar farm, located in the commune of the same name in the Alpes de Haute Provence department in South Region. The 3.7-megawatt Montclar power station, installed over an area of 4.2 hectares, comprises around 8,400 solar panels. It will supply the equivalent of the annual consumption of more than 2,500 inhabitants with green energy. The solar farm benefits from one of the best solar deposits in the country. Construction was a challenge, as the site is located in a mountainous landscape with steep slopes at an altitude of 1,350 metres. The commune is famous for its ski area, in one of the only self-managed resorts in France. Next on the agenda: Q4...

Continue reading

Drip Irrigation Market Size Worth USD 18.70 Billion by 2032 | Emergen Research

Rising investments in the research & development of the agricultural sector and increasing utilization of advanced technologies to increase the efficiency of the traditional irrigation system are driving the demand of the Drip Irrigation Market Vancouver, Nov. 08, 2023 (GLOBE NEWSWIRE) — The global Drip Irrigation Market will be worth USD 18.70 Billion by 2032, according to a current analysis by Emergen Research. The growth of this market can be attributed to the increasing utilization of advanced technologies to increase the efficiency of the traditional irrigational systems. The increasing installations of the Internet of Things (IoT) devices in the agricultural farms are projected to fuel the growth of the industry. The increasing labor cost due to the declining agricultural workforce is expected to drive the development...

Continue reading

22nd Century Group Continues VLN® Expansion, Now Retailing in More Than 5,100 Stores

Adds another 500+ stores BUFFALO, N.Y., Nov. 08, 2023 (GLOBE NEWSWIRE) — 22nd Century Group, Inc. (Nasdaq: XXII), a leading biotechnology company focused on utilizing advanced plant technologies to improve health and wellness with reduced nicotine tobacco, hemp/cannabis and hops, today announced that it has again expanded its VLN® retail presence with more than 500 additional locations across 11 states. With these latest additions, 22nd Century Group’s FDA-authorized VLN® reduced nicotine content cigarettes can now be found at more than 5,100 store locations spanning 23 states, including the addition of Washington, Oregon, Kentucky, and Louisiana. “The addition of over 500 new VLN® sales locations has propelled us beyond the noteworthy milestone of 5,100 stores. Our VLN® sales presence now extends to 23 states, making VLN® available...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.